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Naive CD4+ T cells can differentiate into specific
helper and regulatory T cell lineages in order to
combat infection and disease. The correct response
to cytokines and a controlled balance of these popu-
lations is critical for the immune system and the
avoidance of autoimmune disorders. To investigate
how early cell-fate commitment is regulated, we
generated the first human genome-widemaps of his-
tone modifications that reveal enhancer elements
after 72 hr of in vitro polarization toward T helper 1
(Th1) and T helper 2 (Th2) cell lineages. Our analysis
indicated that even at this very early time point,
cell-specific gene regulation and enhancers were at
work directing lineage commitment. Further exami-
nation of lineage-specific enhancers identified tran-
scription factors (TFs) with known and unknown
T cell roles as putative drivers of lineage-specific
gene expression. Lastly, an integrative analysis of
immunopathogenic-associated SNPs suggests a
role for distal regulatory elements in disease etiology.
INTRODUCTION
Lymphocytes play a pivotal role in the regulation of an immune
response. Upon immunogenic signals from antigen-presenting
cells induced by various pathogenic agents, naive CD4+ T cells
can differentiate into functionally distinct subsets including T
helper 1 (Th1), Th2, Th17, and regulatory T (Treg) cells (Murphy
and Stockinger, 2010; Rautajoki et al., 2008; Weaver et al.,
2007). Each subtype is marked by specific cytokine secretion
patterns (Zhou et al., 2009). These effector and regulatory
CD4+ T cell lineages defend the host from various infections,
while inappropriate activation and differentiation lead to patho-genesis of inflammatory and autoimmune diseases (Hirota
et al., 2011; Reiner et al., 2007).
Molecular mechanisms leading to the polarization of CD4+
subsets have been made clearer through studies that defined
unique signaling molecules and transcription factors (TFs) for
each lineage. Interleukin-12 (IL-12) activates the signal trans-
ducer and activator of transcription 4 (STAT4) and initiates the
differentiation of Th1 cells that secrete the signature cytokine
interferon-g (IFN-g) and express the key transcriptional regulator
TBX21 (T-bet) (Afkarian et al., 2002; Kaplan et al., 1996b; Schulz
et al., 2009). IL-4 in turn initiates Th2 cell differentiation by acti-
vating STAT6 and inducing the key TF GATA-binding protein 3
(GATA-3) and produce cytokines IL-4 and IL-13 (Elo et al.,
2010; Horiuchi et al., 2011; Kaplan et al., 1996a). Although impor-
tant for host defense against intracellular and extracellular path-
ogens, inappropriate execution of Th1 and Th2 cell responses
can lead to pathogenesis of autoimmune and inflammatory dis-
eases (Rautajoki et al., 2008).
Cellular specification requires networks of TFs and epigenetic
mechanisms to mediate changes in gene expression to deter-
mine cell fate (Rothenberg, 2007; Zhang et al., 2012). Previous
studies have demonstrated that lineage specification in Th1
and Th2 cells is represented by the epigenetic state of signature
cytokines loci: The Ifng locus in Th1 cells (Hatton et al., 2006;
Schoenborn et al., 2007) and the Il4 locus in Th2 cells aremarked
by epigenetic modifications (Ansel et al., 2006). Epigenetic
changes bring cellular specificity, as well as plasticity. Th1 cell-
specific gene loci Ifng and Il18r1 are associated with the histone
activating mark H3K4me3 in Th1 cells, whereas in Th2 cells
these loci are marked with the repressive H3K27me3 mark
(Wei et al., 2009). Opposing modifications, H3K4me3 and
H3K27me3—termed ‘‘bivalent domains,’’ are colocalized at
numerous promoter regions in T cells (Roh et al., 2006; Wei
et al., 2009). Surprisingly, this includes genes such as Gata3
and Tbx21, suggesting that lineages may retain some degree
of plasticity even after polarization.
Enhancers play an important role in defining temporal and cell-
specific expression (Bulger and Groudine, 2011; Ong andImmunity 38, 1271–1284, June 27, 2013 ª2013 Elsevier Inc. 1271
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signature for global mapping of enhancer elements (Heintzman
et al., 2009; Heintzman et al., 2007). The use of H3K4me1 has
been used to identify enhancers in human, mouse, zebrafish,
and fly genomes in a predominantly cell-specific manner (Aday
et al., 2011; Creyghton et al., 2010; Ernst et al., 2011; Hawkins
et al., 2011; Heintzman et al., 2009; Ne`gre et al., 2011; Rada-Igle-
sias et al., 2011; Shen et al., 2012). Given the role of enhancers in
driving cell-fate commitment and gene-expression responses to
various stimuli, it is imperative to understand how chromatin
structure defines enhancers that will contribute to induction
and plasticity of T helper cell differentiation to distinct subsets
as well as their role in autoimmune diseases.
In this study, we aimed to characterize the lineage-specific
enhancer repertoire of early differentiating Th1 and Th2 cells rela-
tive to activated CD4+ T cells, by using naive CD4+ cells from
human cord blood.We generated and analyzed global chromatin
state maps from ChIP-seq (chromatin immunoprecipitation
coupled to massively parallel DNA sequencing) by using anti-
bodies recognizing histone modifications that discriminate distal
elements from proximal promoters (H3K4me1, H3K27ac, and
H3K4me3). We focused on 72 hr after polarization in an attempt
to identify early regulators (enhancers and predicted binders) for
these key lineage specifications.At this early stageof thedifferen-
tiation process, the cells are similar, as expected, yet hundreds of
genes are differentially expressed, as determinedby single-mole-
cule sequencing, and thousands of lineage-specific enhancers
often correlate with the gene expression changes. Lastly, under
the principle that improper cell-fate specification can lead to
immunopathogenesis, we found that these lineage-specific
enhancers overlap a great number of SNPs from genome-wide
association studies (GWAS) for various autoimmune disorders,
including type 1 diabetes, rheumatoid arthritis, Crohn’s disease,
and asthma. Several SNPs altered TF binding-site motifs, and a
subset of such SNPs within these predicted sites influenced
TF binding. This provides insight into how SNPs located at
enhancersmay contribute to early human T cell lineage specifica-
tion and disease pathogenesis and is a valuable basis for addi-
tional investigation on the role of TF binding in human disease.
RESULTS
Global Mapping of Early Enhancers
We identified enhancer elements at an early stage of T cell differ-
entiation. We generated global histone modification maps for
H3K4me1 and H3K4me3. These modifications are known to
distinguish enhancer and promoter elements, respectively
(Heintzman et al., 2007). We compared chromatin maps at
72 hr following activation of naive human CD4+ T cells (abbrevi-Figure 1. Genome-wide Mapping and Identification of Lineage-Specifi
(A) Illustration of experimental design for activating the cells (Th0) and for polariz
(B) Global clustering of all predicted enhancers in Th0, Th1, or Th2 cells based o
(C and D) ABHD6 and IFNG loci showing Th2 and Th1 cell-specific enhancer pe
(E and F) Example of lineage-specific nucleosome-free regions (NFR) shown in
downstream of IL-10 and (F) Th2 cell-specific enhancer in an intron of BCAR3
overlapping nucleosome in the other two cell types (dashed rectangle).
(G) Differential gene expression is shown for Th1 and Th2 cells relative to Th0 cells
the other lineage (Th1 or Th2 cells) is shown in red for Th1 cells and blue bars fo
(H) Lineage-specific differential expression relative to Thp cells to accommodateated as Th0 for succinctness) with those 72 hr after polarization
toward Th1 and Th2 cell lineages (Figure 1A). At 72 hr, Th1 cells
were positive for TBX21 protein expression, whereas Th2 cells
were positive for GATA-3 (see Figure S1A available online). At
day 7, the majority of cells expressed key lineage markers as
determined by flow cytometry analysis (Figures S1B and S1C),
indicating the cells polarized to Th1 and Th2 cell-specific line-
ages under these culture conditions.
On the basis of the distinct localization of H3K4me1 relative to
H3K4me3 (Heintzman et al., 2007; see Supplemental Experi-
mental Procedures), we determined 16,507 and 13,466 putative
enhancers for Th1 and Th2 polarized cells, respectively, and
16,552 in the control activated cells (Th0) (corrected p % 0.01;
Table S1A). As expected at this early time point of differentiation,
the chromatin profiles were largely similar between Th1 and Th2
cells and control cells (Figure 1B). Enhancers unique to cells
polarized toward Th1 or Th2 cells could also be determined (Fig-
ures 1C and 1D). To identify lineage-specific enhancers, we
implemented a recent analytical method that searches for sam-
ple-specific nucleosome-free regions (NFR) (He et al., 2010). By
using the histone modification signals, the method first predicts
the nucleosome positions in the samples under consideration,
identifies correctly spaced nucleosome pairs, and then detects
nucleosome depletion in either of the samples. This method
was employed to determine whether peaks that appear similar
in two or more lineages actually represented lineage-specific
enhancer locations due to nucleosome repositioning in active
enhancers at the site of TF binding (Figures 1E and 1F; Figure 2;
Figure S2; Table S1B). By using a stringent selection, we identi-
fied enhancers as lineage-specific if the peaks were called in our
original analysis and contained a NFR relative to both the other
lineage and control cells. That is, to be Th2 cell-specific, the
NFR must be present only in Th2 cell relative to both Th0 and
Th1 cells, indicating a more open chromatin structure in only
Th2 cells. We identified the following number of lineage-specific
enhancers: 2,144 (Th1 cells) and 2,654 (Th2 cells) (Table S2A).
Polarized cells showed a substantial increase in the number of
unique enhancers compared to the 1,636 found in activated cells
(Th0 cells) (Table S2A).
To understand how lineage-specific enhancers might drive
specific gene expression, we generated single-molecule digital
gene expression data by using the Heliscope platform to gain
an accurate tag count of expressed genes in each subtype.
Genes differentially expressed between Th1 and Th0 cells or
Th2 and Th0 cells were identified by using a stringent corrected
p value threshold of 0.01 from a negative binomial model (Anders
andHuber, 2010) and expression fold change ofR1.5 (Tables S4
and S5). We identified 121 genes upregulated in Th1 cells and
292 in the Th2 cell culture condition, whereas 116 werec Enhancer Elements
ing cells to Th1 and Th2 cell subsets.
n H3K4me1. H3K4me3 (promoter modification) is shown as a control.
aks identified through H3K4me1 predictions.
high-density plots for (E) a distal Th1 cell-specific enhancer predicted 9 kb
. The lineage-specific enhancer is determined by nucleosome spacing and
(total genes: blue + gray). Lineage-specific expression relative to Th0 cells and
r Th2 cells.
a three-way comparison.
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Figure 2. Continuum of Enhancer Chro-
matin States
(A) Clustering of Th1 cell-specific H3K4me1-
marked enhancers. H3K27ac reveals active en-
hancers versus poised enhancers that lack
H3K27ac at 72 hr. DNase hypersensitivity data
(DHS) reflecting the active (hypersensitive sites)
and nonactive sites in the cells polarized to Th1 or
Th2 direction for 7 days.
(B) Same as in (A), except for Th2 cell-specific
enhancers.
(C and D) Distribution of enhancer states in Th1
and Th2 cell lineages.
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genes with highly unique expression patterns at 72 hr (Figure 1G;
Table S4A; see Table S5 for all genes). Additionally, all subtypes
showed differential expression relative to naive T helper precur-
sor cells (Thp) (Figure 1H). Consistent with our previous results, a
number of genes become differentially expressed during the
early stage of human Th cell differentiation (Elo et al., 2010;
Lund et al., 2005; Lund et al., 2007). These genes are likely to
be very important for the cell to gain the desired phenotype.
In summary, these chromatin-based enhancer maps provide a
view of lineage-specific gene regulation during early human
T cell specification. These unique enhancers and the bound
TFs may be critical for driving gene expression essential for
each lineage commitment.
Continuum of Enhancer States
A substantial fraction of mammalian enhancers are simulta-
neously marked by H3K27ac (Heintzman et al., 2009), and acet-
ylation islands have enhancer activity (Roh et al., 2007). This is
likely the result of histone acetyltransferases (HATs) that also
act as transcriptional coactivators and bind enhancers, such
as p300 (Heintzman et al., 2009; Heintzman et al., 2007; Shen1274 Immunity 38, 1271–1284, June 27, 2013 ª2013 Elsevier Inc.et al., 2012; Visel et al., 2009). Yet, a sub-
set of enhancers lacks this modification.
Enhancers marked solely by H3K4me1
and lacking H3K27ac are deemed
‘‘poised enhancers’’ as a result of the
absence of the active chromatin modifi-
cation (Creyghton et al., 2010; Hawkins
et al., 2011; Rada-Iglesias et al., 2011).
This also holds true for the lineage-spe-
cific enhancers identified in this study
(Figure 2). The abundance of poised en-
hancers likely reflects the fact that the
cells are at an early stage of differentiation
and beginning to commit to distinct
lineages.
To address the fate of the lineage-spe-
cific enhancers for Th1 and Th2 cells, we
compared our enhancer chromatin maps
to publically available genome-wide
DNase hypersensitivity (DHS) data gener-
ated by the ENCODE consortium for Th1
and Th2 cells after 7–10 days of polariza-
tion (ENCODE Project Consortium, 2011;Maurano et al., 2012). Because DHS reflect an open chromatin
structure, it is indicative of TFs bound to regulatory elements
and presumed active. At this later time point for which DHS
maps were generated, our data suggest the polarized cells are
largely committed based on marker expression (Figures S1B
and S1C). For Th1 and Th2 cell-specific enhancers, about 30%
were active based on histone modifications at 72 hr (Figure 2).
In Th1 cells, 76% of those remained active based on 7–10 day
DHS data, whereas 99% remained active in Th2 cells. Those
that were no longer hypersensitive are likely enhancers used to
drive early lineage specification, but not needed to maintain
the cell-fate commitment. Of the poised enhancers, 21% in
Th1 and 78% in Th2 cells became activated based on DHS
data once the cells are committed to their respective lineages
(Figures 2C and 2D). This suggests that the epigenome is already
primed to regulate the future cell-fate commitment.
STAT6 and Putative Enhancer Binders
Enhancer functionality is driven by the binding of TFs, which in
turn facilitates looping to the target gene promoter and cell-spe-
cific gene upregulation. We analyzed enhancer sequences for
known TFBS motifs to predict sequence-specific TFs as
Immunity
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T cell polarization. Binding of TFs to enhancers were predicted
with ProbTF (La¨hdesma¨ki et al., 2008) by using position-specific
frequency matrices (PSFM) from TRANSFAC (Matys et al., 2006)
and combined with an empirical null model to choose hits above
the background (p < 0.01). Motifs were filtered based on gene
expression to ensure the TFs were expressed in each T cell line-
age. Examination of the identified motifs revealed both new and
known Th cell regulators (Table S2A, bound TFs columns).
Lineage-specific enhancers were enriched for known T cell TF
motifs relative to random genomic background (Table S3;
Experimental Procedures). For Th1 cell-specific enhancers, mo-
tifs included those for key factors STAT1, STAT4, ATF3, and
JUN (Afkarian et al., 2002; Thieu et al., 2008; Filen et al.,
2010). Th2 cell-specific enhancers included motifs for STAT6,
PPARG, BACH, GFI1, NFIL3 and GATA3, which are all upregu-
lated during early Th2 cell differentiation and regulate distinct
genes either independently or in a coordinated fashion. For
example, in the first intron of the GAB2 gene upregulated in
Th2 cells, we identified a Th2 cell-specific enhancer that
harbored a STAT6 motif (Figure 3A). STAT6 is a key regulator
of the Th2 cell lineage by mediating the IL-4 signal (Kaplan
et al., 1996a). Interestingly, GAB2, an adaptor protein, activates
PI3K and Akt, which subsequently regulates IL-4 production
(Frossi et al., 2007). This may provide a key part of the IL-4-
STAT6 regulatory feedback loop. The combination of chro-
matin-based enhancer maps and motif analysis filtered for TFs
expressed in these cells reveals how key TFs are likely to utilize
distal regulatory elements to drive lineage specification. In
another study (Aijo¨ et al., 2012), we identified only a limited num-
ber of enriched motifs for TF binding sites in the promoters of
genes differentially expressed during the early Th cell differenti-
ation, suggesting substantial contribution of enhancer-driven
gene regulation. We also identified motifs in lineage-specific en-
hancers that corresponded to expressed TFs with unknown
roles in Th1 and Th2 cell differentiation for further studies (Fig-
ures 3B–3D; Table S3).
To validate a subset of the enhancers and motif predictions,
we generated ChIP data for at STAT6 motifs within Th2 cell-
associated enhancers. Over 70% of STAT6 binding sites are
enriched over introns and intergenic regions of genome (Elo
et al., 2010). Our motif analysis showed STAT6 motif to be
frequently enriched over Th2 cell-specific enhancers (Figure 3D;
Table S3). We generated ChIP-qPCR data for STAT6,
H3K4me1, and H3K27ac at 4 hr and 72 hr (Figure 4) and vali-
dated six Th2 cell-specific enhancers harboring predicted
STAT6 binding sites. These enhancers were located nearby
genes of known and unexplored function such as RUNX1,
FOXP1, GAB2, IL10RA, SETBP1, and ABHD6, which are upre-
gulated in a Th2 cell-specific manner. We found that H3K4me1
and H3K27ac were enriched at these enhancers in Th2 directed
cells in contrast to naive (Thp) and activated T cells (Th0), which
suggest that these genes are regulated by STAT6 in Th2 cells by
an enhancer-specific manner. STAT6 and H3K4me1 were
largely consistent between 4 and 72 hr, whereas H3K27ac
increased at 72 hr relative to 4 hr. The acquisition of H3K27ac
is likely indicative of later transcriptional events beyond the
initial marking of the enhancer elements (compare Figures 4B
and 4C to Figure 4D).Regulatory SNPs: Overlap of Enhancers with Disease
Associated Variants
Genome-wide association studies (GWASs) have produced
large numbers of disease associated single-nucleotide polymor-
phisms (SNPs). However, many of these studies have failed to
identify causative mutations. This may be, in part, due to many
associated SNPs lying outside of gene coding regions. A recent
assessment of GWASs illustrated that 45% of disease or trait
associated SNPs fell in introns, whereas 43% lie in intergenic re-
gions (Hindorff et al., 2009). Regulatory SNPs (rSNPs) have been
implicated in the altered expression of genes that constitute
expression quantitative traits (eQTLs: for review, see Cheung
and Spielman, 2009). Global methods for determining chromatin
states show that associated SNPs can overlap regulatory re-
gions (Ernst et al., 2011; Gaulton et al., 2010; Maurano et al.,
2012). To determine whether disease-associated SNPs are
potentially rSNPs, we analyzed the vicinities of associated
SNPs from the NHGRI GWAS catalog (Hindorff et al., 2009) for
overlap with our global T helper cell enhancer predictions at
72 hr, including lineage-specific enhancers (see Experimental
Procedures). Several autoimmune disease associated SNP
sets were enriched among all the 460 disease categories (Table
S7), and we decided to conduct a detailed integrated analysis of
the fine-mapped associated SNPs (by using p value cut-off of p <
0.01 for the SNP associations) from asthma (Moffatt et al., 2010),
Crohn’s disease (Duerr et al., 2006; Rioux et al., 2007), multiple
sclerosis (MS) (Hafler et al., 2007), psoriasis (Cargill et al.,
2007; Helms et al., 2003; Nair et al., 2006), rheumatoid arthritis
(RA) (Stahl et al., 2010), type 1 diabetes (T1D) (Barrett et al.,
2009), and ulcerative colitis (UC) (Anderson et al., 2011).
We first looked at the overlap of SNPswith the combined set of
enhancers detected in all three T cell culture conditions. Signifi-
cant (p < 0.001) overlap was found for most of the aforemen-
tioned autoimmune diseases. In total, we determined that
1,281 SNPs overlap our global enhancer maps (Table 1). RA
and UC exhibited the greatest overlap, >400 SNPs each, while
Crohn’s and MS contributed the least, 40 SNPs from each.
As a control, we performed the same analysis for a GWAS study
of age-related macular degeneration (AMD) and age-related cat-
aracts from The Age-Related Eye Disease Study (AREDS) (Age-
Related Eye Disease Study Research Group, 1999), a disease
presumably with little or no association with Th cells. The overlap
of the AREDS SNPs with enhancers was not significant (p value
0.288). When focusing on SNP overlaps with global enhancers
present in each culture condition (Th1 or Th2 or Th0 cells),
some differences between enrichments of overlaps were re-
vealed, such as increased overlap in Th1 cell-conditioned
enhancers for Crohn’s disease (Table S8A). We examined the
distribution of the 1,281 SNPs overlapping enhancer and
found that 50% are at intronic enhancers and 43% are at
distal enhancers (Figure 5A). The disease associated SNPs
were typically within 100–200 kb of the nearest neighboring
gene, even when they were within our mapped enhancers
(Figure 5B).
Next, we focused on the overlap of SNPs with enhancers
selectively detected in Th cells cultured in Th1, Th2, or control
Th0 cell conditions. We identified 76 associated SNPs (Table
S9) from the aforementioned disease GWASs directly overlap-
ping our Th1 cell-specific, Th2 cell-specific, or Th0 cell-specificImmunity 38, 1271–1284, June 27, 2013 ª2013 Elsevier Inc. 1275
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Figure 4. Enhancer and STAT6Motif Valida-
tion by ChIP-qPCR
(A) Time course of Th2 cell polarization and Th0
cells as a control. H3K4me1, H3K27ac, and
STAT6 localization were tested by ChIP-qPCR at
six ChIP-seq determined loci of Th2 cell-specific
H3K4me1 marked enhancers containing STAT6
motifs.
(B) ChIP-qPCR for STAT6 binding at 4 hr and 72 hr
in early stages of Th2 cell polarization. Th0 and
Thp cells serve as controls. Enrichment is a
percent of input.
(C) As in (A), except for H3K4me1.
(D) As in (A), except for H3K27ac. Error bars were
represented as mean ± SEM.
Immunity
Enhancers for Early Th1 and Th2 Polarizationenhancer predictions that are defined by a condition-specific
NFR of 105–250 bp. These include 9 for T1D, 1 for Crohn’s dis-
ease, 2 for MS, 23 for ulcerative colitis, 27 for RA, 3 for psoriasis,
and 11 for asthma (see Table S8B for lineage distributions).
These SNPs were often distributed relatively uniformly across
all three T cell types. The presence of associated SNPs in en-
hancers may alter regulatory networks, disrupt the proper bal-
ance in differentiation to various Th cell subsets, and contribute
to the development of disease.
Inferring Functional Significance of rSNPs
ManySNPswerewithin binding sitemotifs of biologically relevant
TFs. Focusing on theSNPs that overlappedTFBSmotifs in Th cell
subtype-specific enhancers, a number of TFBSmotifswere high-Figure 3. Identification of Putative Enhancer Binders through Motif Analysis
(A) Example of a Th2 cell-specific enhancer in a GAB2 gene intron containing a motif for a known Th2 cell re
(B) Example of a motif at a Th1 cell-specific enhancer upstream of EED, for a TF not previously implicated i
(C and D) Examples of motifs within lineage-specific enhancers for TFs with known and unknown roles in T
Immunity 38, 1271–128ly abundant in a disease-specific manner
(Figure 5C). For example, ATF3, IRF1,
and STAT1 were often occurring in T1D,
whereas VDR and PPARGwere recurrent
at enhancerSNPs forRA. In addition, IRF3
and NF-kB were frequently represented
at asthma rSNPs, and ELF1, STAT6, and
STAT5A were often present for psoriasis.
We also found Th cell subtype-specific
enrichment of TFBS motifs overlapping
rSNPs. Th1 cell-associated rSNPs
frequently overlapped SRF, NFAT1, and
MYB motifs, and Th2 cell associated
rSNPs were regularly present at AP1,
BACH1, STAT6, BCL6, and NF-kB motifs
(Figure 5D).
To gain insight on how enhancers
overlapping variants might alter gene
expression, we attempted to predict
enhancer-promoter interactions by ex-
ploiting the following models used to
correlate or predict enhancer gene tar-
gets: (1) assigning the nearest neigh-
boring (NN) expressed or upregulatedgene to the enhancer; (2) assigning enhancers to genes if both
are between two CTCF binding sites (Hawkins et al., 2011), a
known enhancer blocker (Bell et al., 1999); or (3) correlating
changes in enhancer histone modification(s) with nearby
changes in gene expression (Creyghton et al., 2010; Ernst
et al., 2011), such as correlating changes in enhancer acetylation
(H3K27ac) with changes in nearby gene expression (Kac).
We tested these three models to predict lineage-specific
enhancer gene targets by using only genes expressed in a
Th1-, Th2-, or Th0 cell-specific manner (adjusted p value 0.01,
fold-change > 1.5) (Table S6; see Figure 5E for overlap of predic-
tions by each method). To achieve our CTCF-block model (CB),
we generated maps for CTCF binding by using ChIP-seq in Th1,
Th2, and Th0 cells. The correlation of expression with enhancergulator, STAT6.
n T cell biology.
cell differentiation.
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Table 1. Lead Autoimmune Disease SNPs as Regulatory SNPs
Based on Enhancer Overlap
All Enhancers
Th0-
Specific
Th1-
Specific
Th2-
Specific
# SNPs p Value # SNPs # SNPs # SNPs
Type 1 diabetes (T1D) 126 <0.001 1 5 3
Crohn’s disease 43 0.021 0 1 0
Multiple sclerosis (MS) 42 0.033 0 1 1
Ulcerative colitis (UC) 419 <0.001 5 7 11
Rheumatoid arthritis (RA) 449 <0.001 6 7 14
Asthma 134 0.059 2 4 5
Psoriasis 68 <0.001 1 2 0
AREDS (control) 14 0.288 – – –
Associated lead SNPs were selected based on a p value < 0.01.
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from the enhancer (Table S2B), and only highly correlated
(corr > 0.90) genes were selected. Collectively, the models
determined that during the early stages of human Th cell differ-
entiation 37 and 105 enhancer-target pairs were differentially
activated when the cells are polarized to Th1 and Th2 cell sub-
sets, respectively. Control activated Th cells utilized a distinct
set of 27 enhancer-target pairs (Figure 5E). The lineage speci-
ficity of the enhancers and their predicted targets were in
agreement with the regulatory networks controlling Th cell spec-
ification (Figure S3). This begins to provide a better understand-
ing of lineage-specific gene regulation via enhancer elements.
Next, we intersected enhancers with disease-associated
SNPs and enhancers with predicted target genes. In the case
of ulcerative colitis rSNPs, JAK3, ARRDC2, ATXN1 (see Fig-
ure S4), TNFRSF6B, IL-6, NFkB, GATA3, and IL-10 were pre-
dicted targets. A GATA3 intronic Th2 cell-specific enhancer
overlapped associated SNP rs406103 that altered the PPARG
motif, which is specifically expressed in Th2 polarized cells (Fig-
ures 6A and 6C).
We identified five SNPs associated with T1D in motifs from
different Th1 cell-specific enhancer sites. One such enhancer
was predicted to target CCND2 (Figure 6B), an IL-12 inducible
gene known as a cell-cycle G1-S1 checkpoint regulator and
also associated with aryl hydrocarbon receptor (Ahr) signaling,
IL-8 signaling, p53 signaling pathway and molecular cancer
pathways (Grangeiro de Carvalho et al., 2011; Iwanaga et al.,
2008). The associated SNP rs10774213 lay within the enhancer
region with BACH2 motif (Figures 6B and 6C). The reference
nucleotide at this site is A and the variant is G. The A to G tran-
sition overlaps nucleotide 6 in the BACH2 motif, which is almost
exclusively a G (Figure 6C). The C-to-T change at SNP
rs6043388 was associated with T1D and was present at an in-
tronic enhancer for SIRPG with a CREB motif. CREB plays an
important role in T cell survival and differentiation (Wen et al.,
2010) (Figure 6C).
We found 11 associated SNPs for asthma overlapping our
condition-specific enhancers. Interestingly, one such SNP,
rs2604931, lay within an AHR motif in an activated T cell
enhancer (Th0). This G to A transition alters an exclusively A
nucleotide, at position 5 in the motif, to G. Ahr plays an important
role in setting up Treg versus Th17 cell fates in mice depending1278 Immunity 38, 1271–1284, June 27, 2013 ª2013 Elsevier Inc.on the ligand (Quintana et al., 2008). It remains to be determined
whether it also plays a role in Th1 or Th2 cell specification. The
enhancer with this SNP is predicted to interact with the
MGST2 gene, which is implicated in asthma (Scoggan et al.,
1997; Sjo¨stro¨m et al., 2001; Werz and Steinhilber, 2006). Addi-
tionally, an enhancer within the IL-4R gene contains the associ-
ated SNP rs1805012 that lies within the NFKAPPAB motif
(Figure S4). The reference nucleotide at this site is C and the
variant is T. The C to T transition overlaps nucleotide 10 in the
NFKAPPAB motif, which is exclusively a C (Figure 6C).
In addition to the enhancers listed above, other interesting pre-
dicted gene targets of enhancers harboring variants include
many well-known T cell markers, though some only show a
modest change in expression or p-value (see Table S2A). This in-
cludes AHRR, RHOH, and DUSP16 in T1D. In rheumatoid
arthritis, BATF, IL-2RA, HLA-F (Figure S4), and PRKCQ are pre-
dicted targets. Genetic variation at the IL-2RA gene cluster has
been shown to be associated primarily with autoimmune dis-
eases including T1D, MS, and RA. We found a RA-associated
SNP, rs7904311, at an intronic enhancer of the IL-2RA gene,
which lay within a STAT1 motif, potentially regulating T helper
cell proliferation and differentiation. Though not all SNPs at en-
hancers overlap known motifs, our enhancer target predictions
still allow us to infer some biological significance for these rSNPs
(Table S2). Although no known TFBS overlapped rSNPs for
Crohn’s disease, we could still predict target genes for a subset
of these enhancers, such as GALNT2 (Figure 6C; Figure S4).
Enhancer elements are critical for fine-tuning the expression of
their target genes. SNPs in the enhancers of these target genes
could cause gain or loss of TF binding, and thus may alter the
target gene expression, Th cell differentiation, and ultimately
contribute to disease, especially given that these are enhancers
utilized during early T cell specification.
To determine whether disease-associated rSNPs alter TF
binding at enhancers, and therefore have a functional effect,
we performed DNA Affinity Precipitation Assays (DAPA) by using
the hg18 reference sequence across the predicted motif or
single base-pair variants (associated SNP) as bait. We selected
three SNPs that overlap TF binding sites at predicted lineage-
specific enhancers (Figure 6D). These are the UC-associated
SNP rs406103 at the PPARG motif predicted to target GATA3
in Th2 cells; the RA-associated SNP rs7904311 at the STAT1
motif predicted to target IL-2RA in Th0 cells; and the T1D-asso-
ciated SNP rs604388 at the CREB motif predicted to target
SIRPG in Th0 cells. The selection of SNPs and putative binding
TFs for validation was limited to availability of high quality anti-
bodies for TFs to be used in DAPA. The results show that
PPARG, STAT1, and CREB bound to the predicted TFBS by
using the reference genome as bait sequence and that this TF
binding was decreased when mutant oligonucleotides corre-
sponding to disease associated SNPs were used instead (Fig-
ure 6D; see Figure S5 for replicates and immunoblots). Notably,
the disrupted TF binding caused by the single base-pair change
was roughly equivalent to our control experiment disrupting four
conserved nucleotides in the STAT6motif (Figure 6D; see Exper-
imental Procedures). The results indicated that introduction of a
SNPmutation in the identified TFBS of enhancers alters TF bind-
ing, suggesting a possible mechanism by which SNPs affect
enhancer function and target gene expression.
(legend on next page)
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The control of cell-fate decisions results from complex inter-
actions of signaling and transcriptional regulatory networks
and chromatin structure that can act as a gatekeeper, controlling
DNA access and demarcation of regulatory elements. We used
an enhancer-specific histone modification to generate the first
maps of these elements during the early cell-fate specification
of human T helper cells. By examining Th cells 72 hr after polar-
ization toward the Th1 and Th2 cell lineages, we identified over
30,000 Th cell enhancers, providing insight into early gene regu-
lation and lineage specification. We identified enhancers unique
for Th1 and Th2 cells, suggesting that enhancers function in
lineage-specific gene regulation during early human T helper
cell specification. Furthermore, at this early stage of lineage
commitment, many enhancers were in a poised state based on
chromatin structure. Comparing this poised state with Dnase I
hypersensitivity at 7–10 days, we discovered that many en-
hancers became active upon further polarization, while another
subset remained active both at an early (H3K27ac+) and late
(DHS+) stage of cell-fate commitment. These categories likely
reflect the regulatory changes that are essential to fully commit
to their exact cell fate, as well as the plasticity of Th cells to
respond to external stimuli even after polarization. Examining
the kinetics of STAT6 binding and histone modifications across
a short time course during Th2 cell specification corroborates
this notion of a changing enhancer state. We found that whereas
STAT6 and H3K4me1 were often enriched at 4 hr, H3K27ac
seemed delayed to 72 hr.
Our findings show that chromatin modifications marking
enhancers reflect lineage specification. These enhancers are
enriched for TF binding site (TFBS) motifs representing TFs
that are often expressed in a lineage- or cell-specific manner
and correlate with specific gene expression. Collectively, this
highlights the importance of enhancers in driving unique expres-
sion profiles. Our TFBS motif analysis at predicted enhancer
sequences demonstrated enrichment for both previously un-
known and known lineage-specific Th cell regulators. For
example, Th1 cell-associated enhancers were enriched with
motifs for STAT1, STAT4, ATF3, ETS, IRF, and JUN, whereas
Th2 cell-associated enhancers motifs were enriched for
STAT6, PPARG, BACH, GFI1, NFIL3, and GATA-3. All these
identified TFs were upregulated during early Th1 or Th2 cell dif-
ferentiation and regulate target genes either independently or in
a coordinated fashion. This suggests a means by which key TFs
are likely to utilize distal regulatory elements to drive lineage
specification. We validated several STAT6 predicted motifs atFigure 5. Disease Associated SNPs Directly Overlap with Known TF M
(A) Percent distribution of all disease SNPs at T cell enhancers (Th1, Th2, or Th0 ce
introns (in), promoter proximal (pr-pr), or distal (left in blue), and percent distributio
(pr) overlap was considered.
(B) Histogram of distance of disease SNPs from nearest neighboring gene for SNP
scale up to 5 3 105.
(C) Heatmap of enrichment of TFBS motifs in lineage-specific enhancers containi
right relative to enriched cluster position that is indicated by the color-coded bar
(D) Heatmap of enrichment of TFBS motifs in lineage-specific enhancers containi
the right relative to cluster position that is indicated by the color-coded bar.
(E) Overlap of predicted enhancer target genes for three models: nearest neighb
CTCF block (CB), and enhancer H3K27ac with gene upregulation within 125 kb
1280 Immunity 38, 1271–1284, June 27, 2013 ª2013 Elsevier Inc.Th2 cell-specific enhancers by STAT6 ChIP. The sites were
located nearby genes such as RUNX1, FOXP1, GAB2,
IL-10RA, SETBP1, and ABHD6, which were specifically upregu-
lated in a Th2 cells. This indicates that these genes are likely
regulated by STAT6 in an enhancer-specific manner. Addition-
ally, our recent data reveals that only a fraction of genes that
are differentially expressed during the early stages of Th cell dif-
ferentiation are enriched for TFBS motifs in the promoters (Aijo¨
et al., 2012). This further highlights the role of enhancers and
their importance in priming gene regulation and cell-fate
commitment during the early Th cell differentiation.
The tight regulatory control for proper T helper cell differentia-
tion suggests that perturbations to the system have important
implications for immunopathogenesis. One possible mechanism
for such systematic error is through improper regulatory control
of gene expression critical for a given cell-fate commitment. The
current collection of immunopathogenic GWAS has identified a
large number of disease-associated SNPs that fail to identify
causative genes. Our integrative analysis of chromatin-mapped
regulatory elements not only provides insight into the regulation
of T cell-fate commitment, but also determined that many asso-
ciated SNPs are regulatory SNPs. In several instances these
variants occurred more frequently in known motifs for TFs previ-
ously shown to be important in T helper cell differentiation. Func-
tional validation of a panel of enhancer motifs indicated that
SNPs could alter TF binding. To further our understanding of
the basis of diseases such as asthma, RA, or T1D, we made
use of predicted target genes for enhancers harboring associ-
ated variants to hypothesize that these genes may be affected
by the rSNPs. Our integrative analysis of chromatin state
maps, TFBS motif analysis, and modeling of enhancer-gene
pairs combined with autoimmune GWASs provides new insight
on the basic biology of early T cell differentiation and provides
new avenues of investigation, such as the roles that altered TF
binding and distal regulatory elements play in the etiology of
several immune disorders.
EXPERIMENTAL PROCEDURES
Detailed description of methods for human cord blood CD4+ T cell isolation,
immunoblotting, flow cytometry, ChIP, ChIP-seq, and DAPA can be found in
the Supplemental Experimental Procedures.
Human Cord Blood CD4+ T Cell Culturing
All the data included in this manuscript have been acquired under the permis-
sion from the Ethics Committee of the Hospital District of Southwest Finland.
Purified naive CD4+ T cells were activated with plate-bound anti-CD3
(2.5 mg/ml for coating) and 500 ng/ml soluble anti-CD28 (Immunotech,otifs
ll) identified in this study. The SNPs are categorized by overlap with exons (ex),
n of remaining SNPs categorized similarly (right in red), except direct promoter
s overlapping enhancers (blue) and remaining SNPs (red). Inset shows zoomed
ng disease SNPs clustered by disease. Highly enriched motifs are listed on the
.
ng disease SNPs clustered by lineage. Highly enriched motifs are indicated on
oring upregulated gene (NN), upregulated genes and enhancers within same
(Kac). Venn diagrams are shown for Th0, Th1, and Th2 cells.
(legend on next page)
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Enhancers for Early Th1 and Th2 PolarizationMarseille, France). Th1 cell polarization was initiated with 2.5 ng/ml IL-12 (R&D
Systems, Minneapolis, MN) and Th2 cell neutralizing antibody anti-IL-4 (1 ug/
ml), and 10 ng/ml IL-4 (R&D Systems) plus Th1 cell neutralizing antibody
anti-IFN-g (1ug/ml) to promote Th2 cell differentiation. For neutral Th0
cells, only neutralizing antibody without polarizing cytokines was added.
We added 17 ng/ml IL-2 (R&D Systems) to the cultures at 48 hr (Elo et al.,
2010).
Gene Expression and Analysis
Total RNAwas extracted from naive precursor human cord blood CD4+ T cells,
only activated Th0 cells, and differentiated toward Th1 and Th2 cells at 72 hr by
using Trizol reagent (Invitrogen). For single-molecule, digital gene-expression
sequencing, 1 ug of total RNA was used as starting material and was pro-
cessed according to the Helicos Digital Gene Expression (DGE) Sample Prep-
aration guide. The sequencing data were generated on the Heliscope platform
by Helicos BioSciences, Cambridge. The raw data filtering, alignment to
RefSeq hg18 transcripts, and transcript counting were done using Helicos
Helisphere (https://launchpad.net/helicos/+archive/ppa/+packages). Com-
bination of replicate values and identification of differentially expressed genes
were determined with DESeq (Anders and Huber, 2010).
ChIP-Seq Analysis
Sequenced reads were aligned to genome (version hg18) by using Bowtie
(Langmead et al., 2009). Only uniquely mapping and single read per genome
location were retained. Input measurements were used to correct the read
density profiles. CTCF binding sites were identified by using MACS (Zhang
et al., 2008) and further filtered for more high-confidence peaks by taking
only sites where CTCF motif (from TRANSFAC) was found (p < 1e-4 for motif
scanning when comparing to 20,000 random sequences). Enhancer elements
were detected by using the methods from Heintzman et al. (2007) (H3K4me1
and H3K4me3) and He et al. (2010) (H3K4me1).
Transcription Factor Binding Analysis
Prediction of TF binding was done by using ProbTF (La¨hdesma¨ki et al., 2008)
and TRANSFAC (Matys et al., 2006) version 2009.3. For calculating p values,
the null distribution was estimated by sampling sequences (303 the number
of predicted enhancers) randomly from the genome. TFs with p value < 0.01
were further filtered for expressed ones (DESeq normalized read count >
10). Enrichments of bound TFs were calculated by using binomial test (using
p = 0.01). For exact locations of TF binding, the enhancer areas were scanned
with the TF motifs, and the location with highest score was selected.
Analysis of Enhancer-SNP Overlaps
Disease associated SNPs were downloaded from dbGaP database. Only
SNPs with association with p value < 0.01 were used in overlaps. Enrichment
null distributions were estimated by counting the overlaps of SNPs with
randomly selected locations of sizes equal to the enhancer sets from the
genome (excluding centromeres and telomeres) and repeating this 1,000
times.Figure 6. Potential Regulatory Effects of rSNPs at lineage-specific enh
(A and B) Circos plots for histone modifications, disease associated SNPs - includ
CCND2 (B). The outermost track shows the chromosome bands. Black boxes n
light gray radial lines. The profiles show H3K27ac (orange) and H3K4me1 (blue
overlapping a lineage-specific enhancer are highlighted as empty circles. Innermo
are gray). Arcs connect enhancers to genes based on the target prediction meth
(C) List of a subset of SNPs associated with RA, T1D, ulcerative colitis (UC), and
important role in T cell biology. Crohn’s disease (CD) rSNPs did not overlap with a
further elucidate the potential effect of the SNP. References for gene function ar
(D) DAPA (DNA Affinity Precipitation Assay) experiments to determine whether dis
binding sites at enhancers. Double-stranded oligonucleotides containing the pred
Bindingwasassayedby using nuclear extracts fromactivated (Th0 cell) or polarized
the SNPs at transcription-factor binding sites are shown in 6C (see Supplementa
sequences). DNA sequence with STAT6 binding site and a negative control DNA
provided as controls for DAPA. TF binding to oligonucleotides was detected by im
(see Supplemental Experimental Procedures for antibodies used). Data shown is
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